<DOC>
	<DOCNO>NCT00324194</DOCNO>
	<brief_summary>In study , MGCD0103 , new anticancer drug investigation , give twice weekly patient leukemia myelodysplastic syndrome .</brief_summary>
	<brief_title>A Phase I Study MGCD0103 Given Twice Weekly Patients With Leukemia Myelodysplastic Syndromes</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Mocetinostat</mesh_term>
	<criteria>Patients must diagnosis one following : relapsed refractory AML ALL fail respond standard therapy , progress despite standard therapy . relapsed refractory Myelodysplastic Syndromes include CMML ( chronic myelomonocytic leukemia ) myeloproliferative disorder provide MDS component . previously untreated AML Myelodysplastic Syndromes patient &gt; 60 year age refuse candidate induction chemotherapy Patients relapse refractory CML fail respond imatinib therapy standard therapy , progress despite standard therapy , standard therapy exists . ECOG performance status 0 , 1 , 2 . Age â‰¥18 year . Laboratory requirement . Patients legal representative must able read , understand , sign write informed consent ( approved IRB/EC ) prior study entry . Patients active malignancy except basal cell carcinoma cervical intraepithelial neoplasia ( CIN / cervical situ ) . Patients suspicion CNS involvement ( test require rule CNS involvement absence sign symptom ) . Pregnant lactating woman . Women childbearing potential must negative serum pregnancy test document within 7 day prior registration study . Patients partner , either childbearing potential , use adequate birth control measure throughout course study . Both men woman enrol study must agree use medically acceptable effective form contraception study 90 day follow last dose study medication . An effective form contraception oral contraceptive double barrier method , condom diaphragm . Patients serious illness , medical condition , medical history , include laboratory result , , investigator 's opinion , would likely interfere patient 's participation study , interpretation result . Patients treat investigational drug within 30 day prior study initiation ( investigational drug one approve indication ) , receive concurrent treatment experimental drug anticancer therapy . Known hypersensitivity component MGCD0103 . Known HIV Hepatitis B C ( test need perform rule infection ) . Any psychiatric illness/social situation would , judgment investigator , limit compliance study requirement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Myelodysplastic Syndromes</keyword>
	<keyword>Phase I</keyword>
</DOC>